The study included 22 mUC (18 Her-2 amplification, 3 Her-2 amplification + mutation, 1 Her-2 amplification + overexpression) and reported an ORR of 15.8% (lower than the ORR reported in salivary glands [63.6%], pancreatic [33.3%], colorectal [30.9%], biliary tract [25.7%] and non-small-cell lung cancer [23.8%], but higher than in ovarian [10.0%] and uterine [6.3%] tumors). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.